Gaudium IVF

Q4 FY26Healthcare Services

Gaudium IVF Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹111

Market cap₹846 Cr

P/E36.5

Updated23 Sept 2026

Read4 min read

The short version

Company plans rapid expansion: aiming to increase from 7 hubs to 19 hubs within 3 years. Gaudium IVF expects robust growth driven by rapid expansion: 10 new hubs in FY27, 8 in FY28, and 1 in FY29.

From Gaudium IVF's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Company plans rapid expansion: aiming to increase from 7 hubs to 19 hubs within 3 years.
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25.
Volume growth: 2,255 ovum pickups (cycles) done in FY26; expected to increase with expansion.
Growth driven by hub maturity, higher volume, and international patient influx (~25-30% contribution).
Focus on AI-led embryology and SOP-driven process to maintain clinical excellence during scale-up.
International hubs planned in key locations: Paris, Nigeria, Sydney to boost medical tourism.

2 more points management made on revenue & sales performance

Profitability & Margins

Gaudium IVF expects robust growth driven by rapid expansion: 10 new hubs in FY27, 8 in FY28, and 1 in FY29.
Projected Return on Capital Employed (ROCE) of approximately 35% to 40% over the next 3 to 5 years.
Revenue grew 47.56% in FY26 to INR 104.35 crore; EBITDA increased 31.69% to INR 37.7 crore; PAT grew by 27.7% to INR 24.48 crore.
The company maintains a debt-light balance sheet supporting fully funded expansion primarily through IPO proceeds and internal accruals.
Operating leverage and process-driven SOPs are expected to sustain clinical excellence while scaling.
Introduction of AI-assisted technologies (SiD and ERICA) aims to improve efficiency and success rates, potentially boosting margins.

2 more points management made on profitability & margins

See what Gaudium IVF said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

FY26 capital expenditure was approximately INR 2.11 crore.
For FY27, expected capex is around INR 25 crore.
Capex mainly for new hubs, estimated average cost of INR 2.5 crore per hub.
Funding primarily from IPO proceeds and internal accruals.
Plan to open 10 new hubs in FY27, 8 in FY28, and 1 in FY29.
Strategy involves phased rollout deeper into Tier 2 markets with additional spokes.
Asset-light hub and spoke model to enable capital-efficient scaling.
No current plans to seek private equity; growth funded by IPO proceeds and internal resources.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹955 Cr

Rev 1Mar 1

2Chandan Healthca₹496 Cr

Rev 1Mar 3

3₹65.8K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹658 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

Currently, Gaudium IVF and Women Health Limited operates with a debt-light balance sheet.
As of FY26, total borrowings stood at approximately INR 24.56 crore with a debt-to-equity ratio of 0.16 times, down from 0.45 times in FY25.
The company funds planned expansion primarily through IPO proceeds and internal accruals.
For FY27, capex of INR 25 crore is planned, mainly for new hub openings, financed through internal resources and IPO funds.

2 more points management made on fundraising & capital structure

See what Gaudium IVF said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention a current or expected order book or pending orders for Gaudium IVF and Women Health Limited. However, relevant points related to growth and expansion plans include: - The company plans a rapid expansion with 19 new IVF hubs over the next three years (10 in FY27, 8 in FY28, and 1 in FY29). - Three hubs are expected to be operational within the next couple of months, including a large hub in South Delhi, and others in Nagpur and Gurgaon. - Addition of nine spokes and three international spokes in Paris, Nigeria, and Sydney are planned in the current quarter to increase patient footfall.

2 more points management made on order book & pipeline

Gaudium IVF — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹30 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Gaudium IVF's management said in earlier quarters

Q1 FY27 earnings call analysis →

Others in Healthcare Services this season

Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Apollo Hospitals (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
Health X Platform (Q4 FY26)
Northeast operations growing 50%+ year-on-year and Northern India 25–30%, with plans for 5–7% market share in 2-3 years (Page 10). Key concall takeaways from…
Park Medi World (Q4 FY26)
Total planned capex for the next two years is around INR 500 crores. Key concall takeaways from Park Medi World's Q4 FY26 earnings call — and how it ranks…

Compare:vs Apollo Hospitals vs Max Healthcare Institute Ltd vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Gaudium IVF Q4 FY26 results?

Company plans rapid expansion: aiming to increase from 7 hubs to 19 hubs within 3 years. Gaudium IVF expects robust growth driven by rapid expansion: 10 new hubs in FY27, 8 in FY28, and 1 in FY29.

What is Gaudium IVF share price analysis?

Gaudium IVF currently shows a neutral. The stock trades at a P/E of 36.5 with a market cap of ₹846 Cr. Investors should review the full earnings analysis for detailed insights.

Is Gaudium IVF planning capital expenditure?

FY26 capital expenditure was approximately INR 2.11 crore.

Keep Gaudium IVF on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.